
  <style>
  .gh-table table { 
    border-collapse: collapse; 
    width: 100%;
    border: 1px solid #444;
    font-size: 12px;
  }
  .gh-table th, .gh-table td { 
    border: 1px solid #444; 
    padding: 4px 6px; 
    vertical-align: top;
    font-weight: 400 !important;   /* regular font */
  }
  .gh-table th { 
    .gh-table th { background: #f5f5f5; text-align: left; }
  }
  .gh-table th { font-weight: 700 !important; }
    @media print {
      .gh-table { font-size: 10px; }
    }
  </style>
  <div class='gh-table'><table><thead><tr><th>Molecola (1)</th><th>Molecola (2)</th><th>description</th></tr></thead><tbody><tr><td>Acetylsalicylic acid</td><td>Allopurinol</td><td>The therapeutic efficacy of Allopurinol can be decreased when used in
combination with Acetylsalicylic acid.</td></tr><tr><td>Cabotegravir</td><td>Allopurinol</td><td>The excretion of Allopurinol can be decreased when combined with Cabotegravir.</td></tr><tr><td>Cabotegravir</td><td>Rosuvastatin</td><td>The excretion of Rosuvastatin can be decreased when combined with Cabotegravir.</td></tr><tr><td>Duloxetine</td><td>Acetylsalicylic acid</td><td>Duloxetine may increase the antiplatelet activities of Acetylsalicylic acid.</td></tr><tr><td>Duloxetine</td><td>Allopurinol</td><td>Allopurinol may decrease the excretion rate of Duloxetine which could result in
a higher serum level.</td></tr><tr><td>Nebivolol</td><td>Acetylsalicylic acid</td><td>Acetylsalicylic acid may decrease the antihypertensive activities of Nebivolol.</td></tr><tr><td>Nebivolol</td><td>Duloxetine</td><td>The risk or severity of orthostatic hypotension and syncope can be increased
when Nebivolol is combined with Duloxetine.</td></tr><tr><td>Olmesartan</td><td>Acetylsalicylic acid</td><td>The risk or severity of renal failure, hyperkalemia, and hypertension can be
increased when Olmesartan is combined with Acetylsalicylic acid.</td></tr><tr><td>Olmesartan</td><td>Duloxetine</td><td>The risk or severity of orthostatic hypotension and syncope can be increased
when Olmesartan is combined with Duloxetine.</td></tr><tr><td>Olmesartan</td><td>Nebivolol</td><td>Olmesartan may increase the hypotensive activities of Nebivolol.</td></tr><tr><td>Rilpivirine</td><td>Acetylsalicylic acid</td><td>The metabolism of Acetylsalicylic acid can be decreased when combined with
Rilpivirine.</td></tr><tr><td>Rilpivirine</td><td>Allopurinol</td><td>Rilpivirine may decrease the excretion rate of Allopurinol which could result in
a higher serum level.</td></tr><tr><td>Rilpivirine</td><td>Duloxetine</td><td>The metabolism of Duloxetine can be decreased when combined with Rilpivirine.</td></tr><tr><td>Rilpivirine</td><td>Nebivolol</td><td>The metabolism of Nebivolol can be decreased when combined with Rilpivirine.</td></tr><tr><td>Rosuvastatin</td><td>Allopurinol</td><td>The excretion of Allopurinol can be decreased when combined with Rosuvastatin.</td></tr><tr><td>Rosuvastatin</td><td>Duloxetine</td><td>The metabolism of Rosuvastatin can be decreased when combined with Duloxetine.</td></tr><tr><td>Rosuvastatin</td><td>Rilpivirine</td><td>Rilpivirine may decrease the excretion rate of Rosuvastatin which could result
in a higher serum level.</td></tr></tbody></table></div>
